NASDAQ:TYRA Tyra Biosciences Q3 2026 Earnings Date & Estimates $21.15 +0.26 (+1.24%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$21.15 0.00 (0.00%) As of 11/6/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Tyra Biosciences is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeAfter Market ClosesConference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Tyra Biosciences in Q3 2026Tyra Biosciences is expected to post earnings of -$0.6687 per share. In the same quarter a year earlier Tyra Biosciences reported -$0.50 per share. Tyra Biosciences last reported on August 4, 2026, posting -$0.69 per share and missing the -$0.6499 consensus estimate. Tyra Biosciences has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.6687Prior-Year EPS-$0.50Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.69 (Missed by -$0.0401)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Tyra Biosciences Q3 2026 Earnings FAQ When does Tyra Biosciences report Q3 2026 earnings? Tyra Biosciences (NASDAQ:TYRA) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Tyra Biosciences' Q3 2026 earnings call? Tyra Biosciences' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Tyra Biosciences? Analysts expect Tyra Biosciences to post earnings of -$0.6687 per share for Q3 2026. Tyra Biosciences Earnings HeadlinesTyra Biosciences to Participate in Upcoming Investor ConferencesNovember 5 at 4:05 PM | prnewswire.comTyra Biosciences (TYRA) Set to Release Earnings on WednesdayNovember 3, 2026 | americanbankingnews.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008. | Weiss Ratings (Ad)Tyra Biosciences (TYRA) Stock Looks Rich Against Its Book ValueOctober 31, 2026 | finance.yahoo.comTyra Biosciences (TYRA) Stock Looks Expensive Against Its Book ValueOctober 17, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAOctober 13, 2026 | globenewswire.comSee More Tyra Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email. Email Address About Tyra BiosciencesTyra Biosciences (NASDAQ:TYRA) is a clinical-stage biotechnology company focused on developing precision medicines for patients with cancer and other diseases driven by fibroblast growth factor receptor (FGFR) abnormalities. The company uses its proprietary SNÅP platform to discover and design small-molecule therapies intended to selectively target FGFR alterations while addressing mechanisms of treatment resistance. Tyra’s lead program, TYRA-300, is an oral, selective FGFR3 inhibitor being evaluated in clinical studies for FGFR3-altered urothelial cancer and other potential indications. The company is also developing TYRA-200, a next-generation pan-FGFR inhibitor designed for tumors harboring FGFR2 fusions, rearrangements, or other alterations, including certain forms of cholangiocarcinoma. Its pipeline may expand into additional oncology and genetically driven diseases as development progresses. Founded in 2018 and headquartered in Carlsbad, California, Tyra Biosciences conducts research and clinical development activities in the United States and works through clinical studies to evaluate its therapies in patients with relevant FGFR alterations. The company was founded and is led by Todd Harris, who serves as chief executive officer.View Tyra Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Sandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
